Haematologica (Jul 2019)
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents
- Chiara Tarantelli,
- Lu Zhang,
- Elisabetta Curti,
- Eugenio Gaudio,
- Filippo Spriano,
- Valdemar Priebe,
- Luciano Cascione,
- Alberto J. Arribas,
- Emanuele Zucca,
- Davide Rossi,
- Anastasios Stathis,
- Francesco Bertoni
Affiliations
- Chiara Tarantelli
- Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland
- Lu Zhang
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;Institute of Hematology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
- Elisabetta Curti
- Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland
- Eugenio Gaudio
- Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland
- Filippo Spriano
- Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland
- Valdemar Priebe
- Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland
- Luciano Cascione
- Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland
- Alberto J. Arribas
- Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland
- Emanuele Zucca
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
- Davide Rossi
- Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland;Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
- Anastasios Stathis
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
- Francesco Bertoni
- Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland
- DOI
- https://doi.org/10.3324/haematol.2018.214759
- Journal volume & issue
-
Vol. 104,
no. 7
Abstract
No abstracts available.
